MIP Diagnostics.

Rapid manufacturing of Molecularly Imprinted Polymers for diagnostics.

Molecularly imprinted polymers (MIPs) and nanoMIPs are ideal reagents for a wide range of applications including point-of- care diagnostics and in field-based testing. Using its proprietary processes, MIP Diagnostics can produce a proven nanoMIP for a new target in as little as two weeks.

Technology & Products.

MIPs are nanostructured polymer particles typically containing a single binding site for their target. They can also be fused to solid substrates, such as sensor surfaces. MIP Diagnostics has successfully created and deployed MIPs against all major target classes including peptides, proteins and other macromolecular structures, as well as smaller chemical entities such as drugs, their metabolites and commonly used biochemical species such as enzyme cofactors. MIPs can withstand harsh chemical environments, such as extremes of pH, seawater or high concentrations of organic solvents. They are temperature resistant and have a very long shelf-life without refrigeration.

The Market.

The global market for antibodies and antibody alternatives is growing rapidly (value is c.£85bn) and has been accelerated by the current COVID19 pandemic, creating a sizeable demand for MIP Diagnostics to apply its innovative approach and depth of expertise within the IVD and life sciences industry. MIP Diagnostics’ nanoMIP format is suitable for a wide range of applications including diagnostics, healthcare and bioprocessing.

Business Model.

There are two key strands to the service MIP Diagnostics offers its clients: reagents for purification and separation and the development of “sensor” MIP reagents. Across both strands of its work, MIP Diagnostics offers both “universal” reagents and reagents which have been customised and designed with a particular analytic task or production process in mind.

Fundraising to date.

Since its establishment in 2015 MIP Diagnostics has raised around £7million in funding. This includes capital from Mercia Asset Management, Business Growth Fund, Downing Ventures, Calculus Capital and MIP’s management.

Team.

Chair: Jim Reid
CEO: Stephane Argivier
Director of Technology and Founder: Dr. Antonio Guerreiro
Chief Commercial Officer: Lowri Cope

Contact: enquiries@mip-dx.com | https://www.mip-dx.com/

KEY FEATURES.

9C12A659-F601-4D82-B0B7-58B26B8FB50E

Office space

In oculis quidem se esse vult, summumque malum et, quantum.

Lab space

In oculis quidem se esse vult, summumque malum et, quantum.

Business support

In oculis quidem se esse vult, summumque malum et, quantum.

8BA7CC87-ADB9-4E9E-B6B0-0F609EA2D3A9

Meeting rooms

In oculis quidem se esse vult, summumque malum et, quantum.

Virtual tenancy

In oculis quidem se esse vult, summumque malum et, quantum.

Hot desks

In oculis quidem se esse vult, summumque malum et, quantum.

IP Status

In oculis quidem se esse vult, summumque malum et, quantum.

Opportunity

In oculis quidem se esse vult, summumque malum et, quantum.

Application areas

In oculis quidem se esse vult, summumque malum et, quantum.

Management Team

In oculis quidem se esse vult, summumque malum et, quantum.

27D4EAE4-6FBF-4578-BCBD-4F102E515086

Investment Stage

In oculis quidem se esse vult, summumque malum et, quantum.

1EEFF807-B5A2-4190-89BC-DE59BFF00B15

Investors

In oculis quidem se esse vult, summumque malum et, quantum.

Technology Readiness

In oculis quidem se esse vult, summumque malum et, quantum.

Make An Enquiry.